Join the Chronic Kidney Disease group to help and get support from people like you.
Chronic Kidney Disease News (Page 5)
Related terms: CKD, Chronic Renal Disease, CRD
ASN: Empagliflozin Offers Lasting Cardiorenal Benefit in CKD Patients
MONDAY, Oct. 28, 2024 – Empagliflozin continues to offer cardiorenal benefits for up to 12 months after discontinuation among patients with chronic kidney disease at risk for progression, according...
Comorbid Diabetes Increases Risk for Lower Extremity Amputation With Kidney Disease
FRIDAY, Oct. 18, 2024 – Patients with comorbid diabetes have an elevated risk for lower extremity amputation (LEA) at all stages of chronic kidney disease (CKD) compared with patients without...
Varying Dialysate Calcium Dosage Not Tied to Differences in All-Cause, Cardiovascular Mortality
FRIDAY, Oct. 18, 2024 – There are no significant differences in all-cause or cardiovascular mortality with the prescription of dialysate calcium 1.50 versus 1.25 mmol/L for patients undergoing...
Few With Abnormal Protein Dipstick Results Have Albuminuria Testing
MONDAY, Sept. 30, 2024 – Few patients with abnormal protein dipstick results have follow-up albuminuria quantification, according to a research letter published online Oct. 1 in the Annals of...
Metabolic Surgery Is Renoprotective in Patients With Obesity, CKD
FRIDAY, Sept. 27, 2024 – For patients with obesity, type 2 diabetes, and estimated glomerular filtration rate (eGFR) 20 to 60 mL/min/1.73 m2, metabolic surgery is associated with a lower risk for...
Systemic Immune-Inflammation Index Tied to Mortality in CKD
TUESDAY, Sept. 24, 2024 – There is a J-shaped association between systemic immune-inflammation index (SII) levels and all-cause mortality in patients with chronic kidney disease (CKD), according to...
Sometimes Kidney Stones Need a Little Nudge, Study Finds
MONDAY, Sept. 23, 2024 – Kidney stone fragments sometimes just need a little push to be flushed out of a person’s system, a new trial finds. About seven in 10 patients who got ultrasound treatment t...
Guidance Provided for Management of Obesity in Kidney Disease
MONDAY, Sept. 23, 2024 – In a report issued by the American Society of Nephrology and published online Sept. 18 in the Journal of the American Society of Nephrology, guidance is presented for the...
Homelessness Linked to ESKD, Death in Veterans With Incident CKD
FRIDAY, Sept. 20, 2024 – For veterans with incident chronic kidney disease (CKD), a history of homelessness is associated with an increased risk for end-stage kidney disease (ESKD) and death,...
Ozempic Can Prevent Heart Trouble in Folks With Kidney Issues
THURSDAY, Sept. 12, 2024 – Ozempic and Wegovy can prevent heart problems in overweight and obese people, particularly if they also suffer from kidney disease, a new clinical trial shows. The drugs’ a...
US FDA Approves Jardiance for the Treatment of Adults with Chronic Kidney Disease
RIDGEFIELD, Conn. and INDIANAPOLIS, Sept. 22, 2023 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg tablets to reduce the risk of sustained ...
FDA Approves Kerendia (finerenone) for the Treatment of Patients with Chronic Kidney Disease Associated with Type 2 Diabetes
WHIPPANY, N.J.-- July 9, 2021 (BUSINESS WIRE)-- Bayer announced today the United States (U.S.) Food and Drug Administration (FDA) has approved Kerendia (finerenone), a first-in-class nonsteroidal...
Farxiga Approved in the US for the Treatment of Chronic Kidney Disease in Patients at Risk of Progression With and Without Type-2 Diabetes
30 April 2021 Approval is the most significant advancement in the treatment of chronic kidney disease in more than 20 years In DAPA-CKD Phase III trial, Farxiga demonstrated unprecedented reduction...
FDA Approves Auryxia (ferric citrate) Tablets as a Treatment for People with Iron Deficiency Anemia and Chronic Kidney Disease, Not on Dialysis
BOSTON, Nov. 07, 2017 (GLOBE NEWSWIRE) – Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a company focused on bringing innovative medicines to people with kidney disease, today announced that the U.S....
FDA Approves Amgen's Parsabiv (etelcalcetide) for Secondary Hyperparathyroidism in Adult Patients on Hemodialysis
THOUSAND OAKS, Calif., Feb. 7, 2017 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Parsabiv (etelcalcetide) for the treatment of...